Agoracom Blog Home

Posts Tagged ‘NEO’

AGORACOM Hits 14 Million Twitter Impressions, 3.6 Million YouTube Minutes In 2021. Shatters Engagement Metrics

Posted by AGORACOM-JC at 2:54 PM on Friday, February 25th, 2022
  • AGORACOM Twitter Engagement Metrics Beat Benchmarks By 230%*
  • AGORACOM Cashless Marketing Program Is 100% Compliant With TSXV, CSE and NEO

Last week we were proud to announce another AGORACOM major milestone when we surpassed 710 Million page views (81% AGORACOM / 19% Twitter) from 8.8 Million investors that visited 63.3 Million times over the last 13 years.

These milestones are significant because they continue to demonstrate that AGORACOM is the primary home for serious small cap investors that want to discover their next great small-cap investment.

Today we are proud to announce 2 more major milestones for the 2021 year:

  • 14 Million Impressions On Twitter
  • 3.6 Million Minutes On YouTube

TWITTER SUCCESS – 230% HIGHER ENGAGEMENT SMASHES BENCHMARKS

A picture is worth 1,000 words so our analytics snapshot says it all but we thought you’d like a little additional context to go with it:

MAKE SURE YOU FOLLOW US AND SHARE THE GREAT CONTENT WE CREATE FOR YOU!

If you haven’t seen the incredible year-round content we create for you, please make sure to ask your Account Executive to see it.  Then make sure your social media team is following us so that you can use and share our great content any way you like!

SMALL CAP INVESTORS LOVE AGORACOM VIDEO CONTENT

If a picture is worth 1,000 words, a great video is worth thousands of happy shareholders!

AGORACOM videos receive the highest engagement rates and shareholder testimonials in the industry because we take the time to produce both great content and high production value that viewers truly appreciate.  Click on the image below to see some of our recent great testimonials … or use this link!

MAKE SURE YOU FOLLOW US AND SHARE THE GREAT VIDEOS WE CREATE FOR YOU!

If you haven’t seen the incredible LONG & SHORT video content we create for you, please make sure to ask your Account Executive to see it.  Then make sure your social media team is following us so that you can use and share our great video content with your networks!

HOW DOES AGORACOM CREATE INDUSTRY-LEADING ENGAGEMENT?

The fight for investor attention is stronger than ever.  Within the small cap industry investors are inundated with mountains of information from email to social media. 

Moreover, the small cap industry is now facing stiff new competition for investor attention from the fast-rising Web3 world of Cryptocurrencies, NFTs and Blockchains.

It’s enough to make both investors and issuers dizzy.

AGORACOM overcomes this challenge and wins the battle for investor attention by going the extra mile to create great content. While most firms communicate via “lazy linking” AGORACOM Founder and former lawyer George Tsiolis relies on his communications training to make sure the account management team delivers the following winning variety of content:

FORM – Blogs, Posts, Tweets, Comments, Videos, Audio, Graphics and GIFs

LENGTH – Ultra Long, Long, Medium, Short and Micro

PLATFORMS – YouTube, Twitter, LinkedIn, Facebook, Instagram, Spotify, Search, TikToK (yeah but no dancing!) … and of course our very own AGORACOM.com

Click on the image below to watch a concise but powerful 75-second video to get a great glimpse of our industry-leading content machine … or just click on this link:

This unmatched variety in the form, length and distribution of our content removes all the noise for investors while providing clients with a complete digital marketing solution.       

ZERO $ … AGORACOM CASHLESS AND 100% COMPLIANT PROGRAM

As a small cap company, your cash is invaluable and shouldn’t be used for anything other than operations and growth. You’ll be happy to know The AGORACOM Cashless, Shares For Services Program is fully compliant with the TSX Venture, CSE and NEO Exchanges. As such, it is considered the friendliest comp structure in the entire industry and can be summarized as follows:

  • Shares are issued in 5 X $20,000 installments over the twelve month term.
  • Start Date
    • End Of Q1
    • End Of Q2
    • End Of Q3
    • End Of Q4
  • The number of shares issued is determined by the share price at each date.  As the issuer share price goes higher, the number of shares issued to AGORACOM decreases. 
  • Each issuance comes with customary 4-month hold periods. As such, AGORACOM is a shareholder for at least 16 months (Q4 + 4 Months)
  • Structure means AGORACOM becomes a long-term shareholder that is completely aligned with the Company
  • $0 Cash + the full firepower of AGORACOM

CONCLUSION

Massive audience

+ industry leading engagement

+ industry leading content

+ $0 cash, 100% compliant shares for services = Win – Win

Awakn Life Sciences to Commence Trading on the NEO Exchange Under the Symbol $AWKN

Posted by AGORACOM-JC at 12:18 PM on Wednesday, June 23rd, 2021
  • Strategic focus on developing and delivering psychedelic medicines to treat Addiction.
  • Strong psychedelic drug development pipeline targeting Addiction.
  • First mover advantage for clinics in the UK and the EU with 400m people and CAD$25TR GDP.
  • The leading research and clinical team in the industry focused on using psychedelics to treat Addiction.
  • Multiple scalable revenue streams across drug development and clinical delivery.

Toronto, Ontario–(June 23, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (“Awakn” or the “Company“) a biotechnology company with clinical operations developing, and delivering psychedelic medicines to treat Addiction, is pleased to announce it will begin trading today, June 23, 2021, on the NEO Exchange Inc. (the “NEO”) under the symbol “AWKN”.

“Listing on the NEO is an important milestone for Awakn to continue to build on our dual strategic focus of developing psychedelic drugs, therapies, and enabling technologies to treat Addiction, and delivering psychedelic treatments for Addiction in our clinics,” said Awakn CEO, Anthony Tennyson. “The NEO listing will enable us to accelerate the execution of our drug discovery, therapy development, advanced analytics, and open clinic roll out programs.”

The listing follows the successful completion of the previously announced reverse takeover of a Canadian public company, 2835517 Ontario Ltd., by Toronto-based Awakn Life Sciences Inc. The public company was subsequently renamed Awakn Life Sciences Corp. in connection with the reverse takeover and the listing on the NEO. Additionally, the Company raised gross proceeds of approximately USD$8.3 million through a brokered private placement.

Awakn engaged Canaccord Genuity Corp. and Eight Capital as co-lead agent and joint bookrunners to complete the brokered financing. In connection with the transaction, 2835517 Ontario Ltd. was de-listed from the NEX board of the TSX Venture Exchange.

A filing statement with information about Awakn prepared in accordance with the policies of the NEO is available on SEDAR at www.sedar.com.

About Awakn Life Sciences

Awakn Life Sciences is a biotechnology company with clinical operations, researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat Addiction. Awakn will also deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licencing partnerships globally.

www.awaknlifesciences.com | Twitter | LinkedIn | Facebook

Forward Looking Statements

This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as “forward-looking statements”). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company’s future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates”, “targets” or “believes”, or variations of, or the negatives of, such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved, including statements relating to the proposed NEO listing, and the business of the Company. All forward-looking statements, including those herein are qualified by this cautionary statement.

Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include: whether conditions to the listing on NEO will be satisfied; the business plans and strategies of the Company, the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; and regulatory or political change. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.

Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking information. For more information on the Company, investors are encouraged to review the Company’s public filings on SEDAR at www.sedar.com. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company’s and Awakn’s securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Investor Enquiries:
KCSA Strategic Communications
Valter Pinto / Tim Regan
Phone: +1 (212) 896-1254
[email protected]

Media Enquiries:
America and Canada: KCSA Strategic Communications
Anne Donohoe
[email protected]

Rest of World: ROAD Communications
Paul Jarman / Anna Ramsey
[email protected]

VIDEO – Awakn Life Sciences Corp. $AWKN Is Addressing The Multi-Billion Dollar #Addiction Treatment Industry With #Psychedelics

Posted by AGORACOM-JC at 12:14 PM on Wednesday, June 23rd, 2021

To understand Awakn you first have to understand that …. Psychedelics are going to go through a parabolic, paradigm shifting growth in the next 5 years because of their ability to treat anxiety, depression and addiction … amongst other things Awakn Life Sciences is a biotechnology company with clinical operations developing, and delivering psychedelic medicine to better treat Addiction.  

Awakn has a dual strategic focus: 

  1. Development: Research & developing the next generation of psychedelic drugs, therapies, and enabling technologies to better treat Addiction.
  2. Delivery: Awakn will deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licensing partnerships globally. 

Notable Highlights include: 

  • Strategic focus on better treating Addiction with psychedelics.
  • World leading team focused on psychedelic drug and therapy research. 
  • Strong drug and therapy development pipeline, specifically targeting Addiction.
  • Clinics, which will be the UK and EU’s leading medical psychedelic therapy delivery 
  • Closed $8.3M June 8
  • BRAND NEW LISTING … commencing trading on NEO

Sit back, relax and watch this powerful interview with CEO Anthony Tennyson.